NEXTBIOMEDICAL，快速可吸收微球“Nexsphere-F”：155名患者的临床研究结果发表在《JVIR》上-动脉网

NEXTBIOMEDICAL, Fast Resorbable Microsphere 'Nexsphere-F' : Clinical Study Results on 155 Patients Published in the JVIR

CISION 等信源发布 2025-03-17 20:59



可切换为仅中文







Safety and Excellent Pain Relief Effect after Musculoskeletal Pain Embolization

肌肉骨骼疼痛栓塞后的安全性和优异的镇痛效果

SEOUL, South Korea

韩国，首尔

，

March 17, 2025

2025年3月17日

/PRNewswire/ -- NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for treating joint pain, have been published in the esteemed

/PRNewswire/ -- NEXTBIOMEDICAL CO., LDT宣布，其用于治疗关节疼痛的可吸收栓塞剂Nexsphere-F™的临床研究结果已在著名的

Journal of Vascular and Interventional Radiology (JVIR).

《血管与介入放射学杂志》（JVIR）。

Transcatheter arterial embolization with Nexsphere-F™ was used to address a variety of joint disorders, including knee osteoarthritis, frozen shoulders, symptomatic rotator cuff tears, synovitis of the foot joints, and other refractory overuse injuries. This research was spearheaded by Dr.

使用Nexsphere-F™进行经导管动脉栓塞术治疗了各种关节疾病，包括膝骨关节炎、冻结肩、有症状的肩袖撕裂、足关节滑膜炎及其他难治性过度使用损伤。这项研究由Dr.领导。

Yuji Okuno

奥野裕二

, a globally recognized expert and pioneer in embolization treatment for joint pain. Safety and efficacy were reported in 155 patients.

，全球公认的关节疼痛栓塞治疗专家和先驱。在155名患者中报告了安全性和有效性。

At 6 months, Nexsphere-F™ embolization demonstrated a sustained and substantial reduction of 67% in pain, as assessed using the Numerical Rating Scale, across a broad spectrum of degenerative joint diseases and injuries. Notably, there were no serious adverse events reported in any of the study groups.

在6个月时，使用数字评分量表评估，Nexsphere-F™栓塞术在广泛的退行性关节疾病和损伤中显示出持续且显著的疼痛减少了67%。值得注意的是，所有研究组均未报告严重不良事件。

Post-embolization pain exceeding 7 days occurred in only 5.8%, significantly lower than the rates observed in competing products, in this challenging population..

术后栓塞疼痛超过7天的情况仅发生在5.8%，在这一具有挑战性的人群中显著低于竞争产品所观察到的比率。

NEXTBIOMEDICAL

下一代生物医学

's CTO,

首席技术官，

Eunhye Lee

李恩惠

(Ph.D),

（博士），

stated 'It holds great significance that the safety and efficacy of Nexsphere-F™ have been further validated in Dr. Okuno's study, a prominent figure in the field. Leveraging these promising results, we intend to intensify our sales strategies in the European market and initiate further clinical trials to broaden the indications of Nexsphere-F™ beyond degenerative joint disease to encompass other joint disorders.'.

表示：“Nexsphere-F™ 的安全性和有效性在该领域知名专家奥库诺博士的研究中得到了进一步验证，这具有重大意义。基于这些令人鼓舞的结果，我们计划加强在欧洲市场的销售策略，并启动更多的临床试验，以扩大 Nexsphere-F™ 的适应症范围，超越退行性关节疾病，涵盖其他关节疾病。”

NEXTBIOMEDICAL has received FDA IDE and WCG IRB approval for its pivotal RESORB trial in

NEXTBIOMEDICAL 已获得 FDA IDE 和 WCG IRB 对其关键的 RESORB 试验的批准。

the United States

美国

and is currently recruiting clinical sites. This multicenter study will support FDA approval of Nexsphere-F™ for treatment of painful osteoarthritis, paving the way for its introduction to the U.S. market.

并且目前正在招募临床试验地点。这项多中心研究将支持Nexsphere-F™获得FDA批准用于治疗痛苦的骨关节炎，为其进入美国市场铺平道路。

In the meantime, NEXTBIOMEDICAL has already exceeded its Q4 2024 revenue with sales from January and

与此同时，NEXTBIOMEDICAL 已经通过一月份的销售额超过了其 2024 年第四季度的收入。

February 2025

2025年2月

alone. The company anticipates a 1.5-fold increase in Q1 2025 revenue compared to the previous quarter, indicating sustained sales growth.

单独来看。该公司预计2025年第一季度收入将比上一季度增长1.5倍，表明销售增长将持续。

SOURCE NEXTBIOMEDICAL CO., LTD.

来源：NEXTBIOMEDICAL CO., LTD.

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?